Free tool
FAERS Monitor: Plaquenil
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 009768 or its brand name (Plaquenil, Hydroxychloroquine Sulfate). Reports on generic versions are filed under their own applications.
Reports
91,641
Serious
68,992
75% of reports
Hospitalization
22,904
Death reported
6,486
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective29,383
- rheumatoid arthritis20,611
- pain16,841
- fatigue14,367
- arthralgia14,050
- drug intolerance12,522
- joint swelling12,435
- off label use11,521
- rash10,890
- abdominal discomfort9,834
- contraindicated product administered9,728
- alopecia9,672
- nausea9,604
- systemic lupus erythematosus9,038
- arthropathy8,976
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 639 |
| 2005 | 603 |
| 2006 | 927 |
| 2007 | 1,419 |
| 2008 | 1,525 |
| 2009 | 1,621 |
| 2010 | 1,439 |
| 2011 | 1,640 |
| 2012 | 2,381 |
| 2013 | 2,084 |
| 2014 | 2,448 |
| 2015 | 4,032 |
| 2016 | 4,898 |
| 2017 | 5,675 |
| 2018 | 6,669 |
| 2019 | 8,373 |
| 2020 | 12,455 |
| 2021 | 8,013 |
| 2022 | 6,960 |
| 2023 | 4,564 |
| 2024 | 5,329 |
| 2025 | 5,007 |
| 2026 | 2,940 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,962,518 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| contraindicated product administeredSignal | 9,728 | 108.1 | 105.6 | 702,026 |
| systemic lupus erythematosusSignal | 9,038 | 78.0 | 76.3 | 513,332 |
| rheumatoid arthritisSignal | 20,611 | 50.7 | 50.0 | 826,075 |
| arthropathySignal | 8,976 | 44.0 | 43.1 | 317,119 |
| drug intoleranceSignal | 12,522 | 34.0 | 33.4 | 351,018 |
| joint swellingSignal | 12,435 | 26.2 | 25.8 | 272,382 |
| abdominal discomfortSignal | 9,834 | 14.2 | 14.0 | 114,776 |
| alopeciaSignal | 9,672 | 11.8 | 11.6 | 92,088 |
| arthralgiaSignal | 14,050 | 8.0 | 7.9 | 84,707 |
| painSignal | 16,841 | 6.4 | 6.4 | 77,552 |
| rashSignal | 10,890 | 5.9 | 5.8 | 43,647 |
| drug ineffectiveSignal | 29,383 | 5.2 | 5.2 | 104,285 |
| fatigueSignal | 14,367 | 4.3 | 4.2 | 37,030 |
| off label useSignal | 11,521 | 3.0 | 3.0 | 16,309 |
| nauseaSignal | 9,604 | 2.8 | 2.8 | 11,466 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.